Proceeds from the funding will go to expanding commercialization of the company's FFRangio fractional flow reserve (FFR) coronary vascular physiologic simulation software.

The software produces color-coded 3D renderings of blood flow in the heart's arteries to help physicians with their decision-making, CathWorks said.